What happened
Three new clinical comparisons published this spring put retinaldehyde (retinal) directly against retinol on photoaging endpoints in 12-week protocols. Two of the three were independently funded; the third was sponsored by a brand selling retinal. Across all three, retinal at 0.05%–0.1% performed roughly equivalent to retinol at 0.3%–0.5% — confirming the long-held supplier claim that retinal is "the next step up the conversion ladder."
Why it matters
- For users who tolerate retinol 0.3%, retinal 0.05% is a credible step toward stronger retinoid effects without jumping to prescription tretinoin.
- For users who can't tolerate even 0.1% retinol, retinaldehyde is not the gentle alternative the marketing implies — it's stronger per percent.
- The "retinal is 10× more potent than retinol" claim is roughly right per molecule, but formula matters. A 0.05% retinal serum at pH 5 in a heavily occluded base may outperform a 0.1% retinal in a basic emulsion.
- None of the trials measured deep dermal collagen via histology. Self-reported tolerance and clinician-graded photoaging scales remain the workhorse endpoints.
What to watch next
- Direct retinal vs tretinoin trials. Prescription tretinoin remains the gold standard. Whether retinal closes a meaningful portion of that gap is the next question.
- HPR data. Hydroxypinacolone retinoate is still primarily backed by supplier studies. Independent comparison would be useful.
- Combination products. Retinal + bakuchiol and retinal + peptide stacks are dominating launches in 2026. Independent head-to-head trials are still rare.